These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6083913)

  • 1. [Immunoradiometric determination of blood/tissue plasminogen activators in thrombophilia].
    Astedt B; Fagner U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):475-9. PubMed ID: 6083913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma.
    Brommer EJ; Verheijen JH; Chang GT; Rijken DC
    Thromb Haemost; 1984 Oct; 52(2):154-6. PubMed ID: 6441302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypofibrinolysis and thrombophilia].
    Cepelák V; Dvorák J; Cepeláková H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):456-67. PubMed ID: 6083911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered endothelial function following the Fontan procedure.
    Binotto MA; Maeda NY; Lopes AA
    Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrinsic plasminogen activator response to exercise after a single dose of propranolol.
    el-Sayed MS
    Med Sci Sports Exerc; 1992 Mar; 24(3):327-32. PubMed ID: 1549027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
    Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
    J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic parameters in patients undergoing total hip replacement: relationship with the development of asymptomatic deep vein thrombosis and diagnostic usefulness of venous occlusion.
    Trotti R; Siragusa S; Rondanelli M; Chezzi L; Citterio A; Melzi d'Eril GV; Piovella F
    Haematologica; 1997; 82(2):178-81. PubMed ID: 9175322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients--analysis of responders and non-responders.
    Brommer EJ; Barrett-Bergshoeff MM; Allen RA; Schicht I; Bertina RM; Schalekamp MA
    Thromb Haemost; 1982 Oct; 48(2):156-61. PubMed ID: 6817444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic response in women on low-dose oral contraceptive.
    Ishak R; Ahmad R; Gudum HR; Hassan K; Ang ES
    Malays J Reprod Health; 1992 Jun; 10(1):7-11. PubMed ID: 12345026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behaviour and quantitation of extrinsic (tissue-type) plasminogen activator in human blood.
    Kluft C; Jie AF; Allen RA
    Thromb Haemost; 1983 Aug; 50(2):518-23. PubMed ID: 6356452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolytic response to exercise in women using third-generation oral contraceptives.
    Weiss C; Walter B; Dorsch MF; Bärtsch P
    Blood Coagul Fibrinolysis; 2006 Oct; 17(7):563-8. PubMed ID: 16988552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men.
    Prowse CV; Farrugia A; Boulton FE; Tucker J; Ludlam CA; McLaren M; Belch JJ; Prentice CR; Dawes J; MacGregor IR
    Thromb Haemost; 1984 Feb; 51(1):110-4. PubMed ID: 6426076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis and the risk of venous and arterial thrombosis.
    Meltzer ME; Doggen CJ; de Groot PG; Rosendaal FR; Lisman T
    Curr Opin Hematol; 2007 May; 14(3):242-8. PubMed ID: 17414214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
    Crowther MA; Roberts J; Roberts R; Johnston M; Stevens P; Skingley P; Patrassi GM; Sartori MT; Hirsh J; Prandoni P; Weitz JI; Gent M; Ginsberg JS
    Thromb Haemost; 2001 Mar; 85(3):390-4. PubMed ID: 11307802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator levels in plasma and urine during exercise and oral contraceptive use.
    Hedlin AM; Milojevic S; Korey A
    Thromb Haemost; 1978 Jun; 39(3):743-50. PubMed ID: 705703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of DDAVP infusion on the coagulation and fibrinolytic response to surgery.
    Melissari E; Scully MF; Paes T; Ellis V; Kakkar VV
    Thromb Haemost; 1986 Feb; 55(1):54-7. PubMed ID: 3085264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lysine-absorbable plasminogen activator is elevated in conditions associated with increased fibrinolytic activity.
    Comp PC; Jacocks RM; Rubenstein C; Radcliffe R
    J Lab Clin Med; 1981 May; 97(5):637-45. PubMed ID: 6783711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.